“FIB-4 ≥1.3 Is Correlated With Increased DKD Risk in T2D, But SGLT2i Therapy That Lowers FIB-4 Attenuates This ”. Diabzen 3, no. 4 (December 15, 2025): 120–127. Accessed April 14, 2026. https://www.thediabzen.com/index.php/d/article/view/34.